A specific VEGF-R tyrosine kinase inhibitor enhances the antiproliferative effect of trastuzumab in ErbB-2 overexpressing breast cancer cells

被引：0
|
作者：
Kim, E. [1 ]
Lobocki, C. A. [1 ]
Dubay, L. [1 ]
Mittal, V. [1 ]
机构：
[1] Providence Hosp, Med Ctr, Southfield, MI 48037 USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2007年 / 14卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：48 / 49
页数：2
相关论文
共 50 条
  • [21] Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ErbB-2 inhibitor lapatinib
    Burris, HA
    ONCOLOGIST, 2004, 9 : 10 - 15
  • [22] ETHANOL ENHANCES THE INTERACTION OF BREAST CANCER CELLS OVEREXPRESSING ERBB2 WITH EXTRACELLULAR MATRIX
    Luo, J.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2010, 34 (06) : 265A - 265A
  • [23] Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
    Xia, WL
    Gerard, CM
    Liu, LH
    Baudson, NM
    Ory, TL
    Spector, NL
    ONCOGENE, 2005, 24 (41) : 6213 - 6221
  • [24] Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
    Wenle Xia
    Catherine M Gerard
    Leihua Liu
    Nathalie M Baudson
    Thierry L Ory
    Neil L Spector
    Oncogene, 2005, 24 : 6213 - 6221
  • [25] Reishi sensitizes EGFR-overexpressing inflammatory breast cancer cells to the tyrosine kinase inhibitor erlotinib
    Suarez-Arroyo, I. J.
    Maldonado-Martinez, G.
    Cubano, L. A.
    Martinez-Montemayor, M.
    MOLECULAR BIOLOGY OF THE CELL, 2014, 25
  • [26] ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a γ-secretase inhibitor
    C Osipo
    P Patel
    P Rizzo
    A G Clementz
    L Hao
    T E Golde
    L Miele
    Oncogene, 2008, 27 : 5019 - 5032
  • [27] Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells
    Esparis-Ogando, A.
    Ocana, A.
    Rodriguez-Barrueco, R.
    Ferreira, L.
    Borges, J.
    Pandiella, A.
    ANNALS OF ONCOLOGY, 2008, 19 (11) : 1860 - 1869
  • [28] Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer
    Burstein, Harold J.
    Sun, Yan
    Dirix, Luc Y.
    Jiang, Zefei
    Paridaens, Robert
    Tan, Antoinette R.
    Awada, Ahmad
    Ranade, Anantbhushan
    Jiao, Shunchang
    Schwartz, Gary
    Abbas, Richat
    Powell, Christine
    Turnbull, Kathleen
    Vermette, Jennifer
    Zacharchuk, Charles
    Badwe, Rajendra
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) : 1301 - 1307
  • [29] ON-III inhibits erbB-2 tyrosine kinase receptor signal pathway and triggers apoptosis through induction of Bim in breast cancer cells
    Li, Dan-Dan
    Wu, Xiao-Qi
    Tang, Jun
    Wei, Xiao-Yi
    Zhu, Xiao-Feng
    CANCER BIOLOGY & THERAPY, 2009, 8 (08) : 739 - 743
  • [30] ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a γ-secretase inhibitor
    Osipo, C.
    Patel, P.
    Rizzo, P.
    Clementz, A. G.
    Hao, L.
    Golde, T. E.
    Miele, L.
    ONCOGENE, 2008, 27 (37) : 5019 - 5032
12345